Her name is Theresa May and she is the leading candidate to challenge Boris Johnson for Prime Minister. She is also a recently diagnosed Type 1 diabetic. Let's get her on Afrezza, and maybe we can start selling the drug in the UK.
No it doesn't mean more frequent dosing. It's a mealtime insulin, not a basal insulin. And so what it leaves the body faster? It causes fewer hypoglycemic events, which hospitalizes 100,000 people a year and can be fatal. Now I'm putting you back on ignore where you belong.
The news was bullish, but the market is manic-depressive when it comes to MNKD. Right now it's in its depressive, "show me the money" phase. When the sales start flowing in a few weeks, the stock will jump.
SLIM. Mannkind represents .7% of total assets as of inception, or about $17 million. If they bought shares at $1, they own over 3% of the company. If it catches on, that'll be another source of buying.